Neuropathix, Inc.
20.7.2021 15:01:52 CEST | ACCESS Newswire | Press release
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 "Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders."
One of the compounds disclosed as part of this PCT Patent is the Company's proprietary ingredient LEA™. LEA™ is the trademark and acronym for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine, the designated International Nomenclature Cosmetic Ingredient (INCI) name assigned by Personal Care Products Council (PCPC) for the Company's patented monotherapeutic compound.
"A few years ago we were asked if we had a compound to treat radiation dermatitis, a significant problem for patients undergoing chemotherapy and radiation treatments for breast cancer. Of the CBD analogues that we developed, we felt that LEA™ was best to test in parallel with cannabidiol and tacrolimus. The preclinical results were very promising and brought us to not only patenting these select compounds, but also formulating a cream which we believe may be useful for relief of symptoms across several disorders. We are now looking at launching two branded products containing LEA™, which we currently expect will happen sometime between the first and second quarter of 2022," said Dean Petkanas, CEO of Neuropathix.
LEA™, the Company's novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. Although both compounds were effective in preventing the release of TNF-alpha (TNFα), only LEA™ was found to be effective in preventing the release of IL-1-beta (IL-1β) from human epidermal cells. The experiments completed to date suggest that LEA™ may be more effective than cannabidiol ("CBD") in preventing inflammatory responses relevant to UVB-radiation.
Additionally, LEA™ was shown in preclinical testing to decrease inflammatory cytokine (TNFα, IL-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. LEA™ was shown to be effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and is currently among the targets believed to be creating the cytokine storm in SARS-CoV-2 ("COVID-19").
The market demand for products that defend against harmful UVB and UVA radiation has surged in recent years. Sun care products have moved from solely being intended for skin care to being a multifunctional first line of defense to sun exposure. The global sun care market has witnessed significant growth and is projected to reach $24.9 billion USD by 2024, while the global skin care products market is projected to reach $183.03 billion USD by 2025.
About Neuropathix, Inc.
Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation, socially responsible pain management and neuroprotective therapeutics to treat patients with significant unmet medical needs. Over the past ten years, Neuropathix has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel, new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. The Company's family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management, and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Neuropathix, visit www.neuropathix.com and the Company's Twitter page at @neuropathix.
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, including, without limitation, the Company's business plan, plan of operations, the viability of the Company's drug candidates, the targeted beneficial effects of LEA™, the sun care and skin care markets, the Company's position, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Media Relations:
Thoma Kikis
Chief Communications Officer
P: 917-652-2479
E: thoma@neuropathix.com
www.neuropathix.com
Investor Relations:
Louie Toma
Managing Director
CORE IR
P: 516-222-2560
E: louie@coreir.com
www.coreir.com
SOURCE: Neuropathix, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655929/Neuropathix-Inc-Announces-Publication-of-PCT-Patent-Application-for-the-Treatment-of-Radiation-Dermatitis-and-Other-Skin-Disorders
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clockwork.io Launches The Industry's First Contractual Commitment to End GPU Waste in AI Training1.7.2026 17:00:00 CEST | Press release
"You Only Compute Once" (YOCO) guarantees to resolve 90% of AI training failures with no lost progress, or customers get credit PALO ALTO, CA / ACCESS Newswire / July 1, 2026 / Clockwork.io, pioneer of Software-Driven AI Fabrics™ and the company behind TorchPass AI fault tolerance, today announced the YOCO Guarantee - the industry's first contractual commitment to dramatically reduce the hidden, compounding cost of training failure in large-scale AI infrastructure. The announcement marks a turning point in how the AI industry measures infrastructure reliability - moving beyond uptime metrics designed for a previous era towards goals AI teams value most: whether the job finishes on time, without losing work. Under the YOCO (You Only Compute Once) Guarantee, Clockwork.io commits that at least 90% of training failures on supported TorchPass workloads will be resolved through live GPU migration, with no lost training progress, no checkpoint rollback, and no recompute. If Clockwork.io falls
Hydrosat Launches Data Discovery Platform, Unlocking 500 Million sq km of Satellite Imagery1.7.2026 15:00:00 CEST | Press release
New portal provides on-demand thermal imagery for critical resource monitoring, risk detection, and operational decision-making worldwide. WASHINGTON, D.C. AND LUXEMBOURG CITY, LUXEMBOURG / ACCESS Newswire / July 1, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced the launch of its new Discovery Portal, a centralized gateway for customers to access, explore, and leverage thermal imagery and analytics from space. The Discovery Portal enables organizations to access and evaluate thermal intelligence products powered by Hydrosat's flagship 30 m pixel-size Land Surface Temperature data set and growing constellation of thermal infrared satellites. Unlike traditional optical imagery, thermal imagery captures heat signatures from the Earth's surface, providing actionable insights across vast geographic areas, day or night, and often in conditions where conventional imaging is limited. With over 500 million sq km of imagery alre
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202630.6.2026 20:55:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2026 of $35,855,341 Total cash as at April 30, 2026 of $664,328 Working capital deficiency as at April 30, 2026 of $2,683,766 Shareholder's equity as at April 30, 2026 of $32,258,687 During the three-month period ended April 30, 2026, the Company incurred $57,783 in cost for exploration activities at the TBN project. During the quarter, the Company has been pursuing project financing alternatives while continuing to advance critical aspects of the project including progressing Advanced Exploration permitting discussions, and detailed planning for the next phase of exploration at E
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
Human-Robot Collaboration Takes Center Stage at Prestigious Logistics Award30.6.2026 15:00:00 CEST | Press release
Denmark's The Mobile Robot Company wins IFOY Industrial Truck of the Year 2026 with a self-driving pallet jack built to empower warehouse operators rather than replace them. STUTTGART, DE / ACCESS Newswire / June 30, 2026 / In warehouses and factories, much of the work that keeps goods moving is still measured in footsteps. Operators walk the same routes, push the same loads, and repeat the same transport tasks hour after hour. For years, automation has promised to remove that work, but often with a catch: complex projects, fixed infrastructure, long integrations, and systems that assume people should be designed out of the process. At this year's IFOY AWARD, one of intralogistics' most respected technology prizes, the Industrial Truck of the Year award went to a different idea. The Mobile Robot Company, a young Danish robotics startup, won the 2026 title for the J1600 self-driving pallet jack, a robot designed not to replace the warehouse operator, but to work under the operator's dir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom